$TAK News

CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est

Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B

Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate

Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials

Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance

Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine

Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis

Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients

FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIO

Jury Hits Takeda With $885 Million Antitrust Verdict

Takeda's Rich Pipeline Optionality Is Worth A 'Buy'

Takeda Pharmaceutical Q4 Earnings Call Highlights

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.

Takeda Pharmaceutical Co Sees FY2026 Adj EPS $3.01; Sees Sales $29.585B

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate